Market Access Medicare drug pricing negotiations: What comes next? Last month, the US Centers for Medicare and Medicaid Services released the negotiated prices for the first 10 drugs subject to the
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face